SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is garnering significant investor attention as the community anticipates Phase 3 trial data, with discussions heavily focused on the drug's best-in-class potential and the prospect of M&A activity. Market participants are closely tracking the upcoming Goldman Sachs fireside chat, weighing the potential for a data-driven rerate against ongoing concerns regarding market volatility and manipulative trading patterns.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is gaining significant attention as a specialized infrastructure provider for AI factory deployments, with community members focused on its integration of CXL memory technology and strategic partnerships with major hardware vendors. Investors are closely tracking its role in overcoming memory-bound AI inference bottlenecks, with bullish sentiment driven by its production-level server solutions and potential for sector-wide re-rating.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense investor attention as the market anticipates critical Phase 3 topline data readouts for its MDD and GAD programs, with community members actively debating whether these upcoming results will validate the company's valuation or lead to further volatility. Investors are closely monitoring the company's significant cash burn rate and potential for future dilution while weighing its clinical-stage pipeline against established psychedelic sector leaders like Compass Pathways.

Vishay Intertechnology, Inc. engages in the manufacture and distribution of discrete semiconductors and passive electronic components. It operates through the following segments: MOSFET (metal oxide semiconductor field-effect transistor), Diodes, Optoelectronic Components, Resistors, Inductors, and Capacitors. The MOSFET segment offers semiconductors which function as solid state switches to control power. The Diodes segment produces semiconductors which route, regulate, and block radio frequency, analog, and power signals, protect systems from surges or electrostatic discharge damage, and provide electromagnetic interference filtering. The Optoelectronic Components segment includes components that emit light, detect light, or do both. The Resistors and Inductors segment deals with components that impede electric current. The Capacitors segment provides components which store energy and discharge it when needed. The company was founded by Felix Zandman in 1962 and is headquartered in Malvern, PA.

Vishay Intertechnology, Inc.

Vishay Intertechnology is trending as institutional investors capitalize on its pivotal role in the high-demand semiconductor and AI-linked infrastructure supply chain, with community members noting the stock's resilient technical breakout to record highs. Discussions center on its steady trend performance across power electronics and robotics, positioning it as a structural leader in the ongoing expansion of physical AI compute capacity.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is seeing intense volatility and active community debate after delivering a massive earnings beat that was quickly overshadowed by investor concerns over future guidance and solar sector headwinds. While bulls point to the company's strong revenue growth and dominant position in residential energy as an undervalued opportunity, bears are highlighting risks from high debt levels and potential regulatory shifts that have fueled heavy short interest and aggressive price swings.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is experiencing a surge in community engagement as investors look for exposure to the physical AI and autonomous delivery sector, driven by anticipation of upcoming earnings and recent expansions in partnership deals. While some market participants are cautious due to share dilution concerns and high short interest, bulls are highlighting the company's fleet scaling and long-term potential as a key player in the robotics ecosystem.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is attracting significant attention as investors track its expansion into AI-driven data center power infrastructure and automotive semiconductor demand. Community sentiment remains focused on the company's technical inflection points, analyst target revisions, and its critical role in supporting efficient power management for high-density AI compute stacks.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending as traders react to its recent listing on major platforms and debate its utility as a governance token for a decentralized reinsurance marketplace. The community is actively analyzing its institutional backing and tokenomics, with many watching for potential price discovery after it broke through key resistance levels.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining traction as investors focus on its v4 launch and a revenue-sharing model that provides stakers and node runners with earnings from its decentralized GPU compute network. Community members are emphasizing the project's significant supply shock, noting that a high percentage of tokens are currently locked in long-term staking, which they believe creates a bullish environment for this infrastructure-focused asset.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is gaining momentum as a key supplier in the AI infrastructure stack, with the community highlighting its essential role in supplying power-management silicon for AI-driven data centers and high-density GPU clusters. Investors are closely monitoring its strengthening institutional accumulation and technical breakout as the company shifts from a legacy automotive-industrial focus to a high-growth AI semiconductor powerhouse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.31, moving 2.96% from the previous trading session.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.

Here's Why You Should Hold Avantor Stock in Your Portfolio for Now

AVTR's product breadth, digital upgrades and new pharma wins support growth, though VWR Distribution & Services remains a challenge.

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?

Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.

Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Pacific Biosciences of California Inc

PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

PACBPacific Biosciences of California Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PACB News